Skip to content
All articles

Phase 2 trial of adjuvant capecitabine-based oral chemotherapy plus trastuzumab for small HER2-positive, node-negative breast cancer

Prof. Zhi-Ming Shao
Prof. Zhi-Ming Shao

Adjuvant treatment decisions for patients with small (T≤1 cm), node-negative, HER2-positive breast tumors remain challenging. The phase 2 ORCHID study at Fudan University Shanghai Cancer Center (China) evaluated an oral chemotherapy plus trastuzumab regimen in this population. Eligible patients received either single-agent capicitabine (n=176) or vinorelbine (n=5) plus trastuzumab, followed by trastuzumab monotherapy for a total of 12 months of therapy. The primary endpoint was disease-free survival (DFS). Among the 182 included patients, 81% had tumors measuring ≤0.5 cm and 74% had HR-negative disease. After a median follow-up of 5.7 years (range 1.0-6.2), the 5-year DFS rate was 97.3% (90% CI 94.4-98.7), with the lower bound of the 90% CI exceeding the prespecified threshold of 92%, meeting the primary endpoint. Among 6 observed invasive disease events, 2 involved distant metastasis, 3 involved local or regional recurrence, and 1 involved contralateral breast cancer. The 5-year distant disease-free survival rate was 97.2% and the 5-year overall survival rate was 100%. Among the 176 patients treated with capecitabine, the most common treatment-related adverse events was hand-foot syndrome, occurring in 66.5% of patients (grade 3 in 8.0%). The authors conclude that among women with HER2-positive, node-negative breast tumors measuring ≤1 cm, capecitabine-based oral chemotherapy plus 1 year of trastuzumab was associated with a low risk of cancer recurrence and favorable toxicity.

Original publicationlink.springer.com
Read the publication